首页 > 最新文献

American Journal of Clinical Dermatology最新文献

英文 中文
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study
IF 8.6 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-02-03 DOI: 10.1007/s40257-025-00922-2
Siddhartha Sood, Alexander Rimke, Brian D. Rankin, Abrahim Abduelmula, Jorge R. Georgakopoulos, Khalad Maliyar, Ahmed Bagit, Fernejoy Leung, Alim R. Devani, Ronald Vender, Jensen Yeung, Vimal H. Prajapati
{"title":"Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study","authors":"Siddhartha Sood, Alexander Rimke, Brian D. Rankin, Abrahim Abduelmula, Jorge R. Georgakopoulos, Khalad Maliyar, Ahmed Bagit, Fernejoy Leung, Alim R. Devani, Ronald Vender, Jensen Yeung, Vimal H. Prajapati","doi":"10.1007/s40257-025-00922-2","DOIUrl":"10.1007/s40257-025-00922-2","url":null,"abstract":"","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 2","pages":"301 - 304"},"PeriodicalIF":8.6,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143121734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.
IF 8.6 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-31 DOI: 10.1007/s40257-025-00924-0
Allison Yan, Lauren Madigan, Abraham Korman, Sabrina Shearer, Brittany Dulmage, Tejesh Patel, Nima Milani-Nejad, Catherine Chung, Kristopher Fisher, Benjamin Kaffenberger

Morbilliform eruptions, which are a clinical reaction pattern characterized by erythematous macules and papules coalescing into patches that cover most of the skin surface, are one of the most common cutaneous findings in the inpatient setting. In the hospital setting, most causes are benign and due to low-risk drug exanthems; however, morbilliform eruptions may also be a sign of high-risk diseases, including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, acute generalized exanthematous pustulosis, and graft-versus-host disease. Proper identification of the etiology and risk stratification of a morbilliform eruption is critical to ensure proper management and optimize patient outcomes. In this review, we discuss the key features that differentiate high-risk from low-risk morbilliform eruptions, as well as specific characteristics that differentiate the different high-risk eruptions. Additionally, we offer a clinical algorithm that may be applied in the management of a patient who presents with a morbilliform rash.

{"title":"Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.","authors":"Allison Yan, Lauren Madigan, Abraham Korman, Sabrina Shearer, Brittany Dulmage, Tejesh Patel, Nima Milani-Nejad, Catherine Chung, Kristopher Fisher, Benjamin Kaffenberger","doi":"10.1007/s40257-025-00924-0","DOIUrl":"https://doi.org/10.1007/s40257-025-00924-0","url":null,"abstract":"<p><p>Morbilliform eruptions, which are a clinical reaction pattern characterized by erythematous macules and papules coalescing into patches that cover most of the skin surface, are one of the most common cutaneous findings in the inpatient setting. In the hospital setting, most causes are benign and due to low-risk drug exanthems; however, morbilliform eruptions may also be a sign of high-risk diseases, including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, acute generalized exanthematous pustulosis, and graft-versus-host disease. Proper identification of the etiology and risk stratification of a morbilliform eruption is critical to ensure proper management and optimize patient outcomes. In this review, we discuss the key features that differentiate high-risk from low-risk morbilliform eruptions, as well as specific characteristics that differentiate the different high-risk eruptions. Additionally, we offer a clinical algorithm that may be applied in the management of a patient who presents with a morbilliform rash.</p>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Individualized Neoantigen-Directed Melanoma Therapy
IF 8.6 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-29 DOI: 10.1007/s40257-025-00920-4
Karam Khaddour, Elizabeth I. Buchbinder

Individualized neoantigen-directed therapy represents a groundbreaking approach in melanoma treatment that leverages the patient’s own immune system to target cancer cells. This innovative strategy involves the identification of unique immunogenic neoantigens (mutated proteins specific to an individual’s tumor) and the development of therapeutic vaccines that either consist of peptide sequences or RNA encoding these neoantigens. The goal of these therapies is to induce neoantigen-specific immune responses, enabling the immune system to recognize and destroy cancer cells presenting the targeted neoantigens. This individualized approach is particularly advantageous given the genetic heterogeneity of melanoma, which exhibits distinct mutations among different patients. In contrast to traditional therapies, neoantigen-directed therapy offers a tailored treatment that potentially reduces off-target side effects and enhances therapeutic efficacy. Recent advances in neoantigen prediction and vaccine development have facilitated clinical trials exploring the combination of neoantigen vaccines with immune checkpoint inhibitors. These trials have shown promising clinical outcomes, underscoring the potential of this personalized approach. This review provides an overview of the rationale behind neoantigen-directed therapies and summarizes the current state of knowledge regarding personalized neoantigen vaccines in melanoma treatment.

{"title":"Individualized Neoantigen-Directed Melanoma Therapy","authors":"Karam Khaddour,&nbsp;Elizabeth I. Buchbinder","doi":"10.1007/s40257-025-00920-4","DOIUrl":"10.1007/s40257-025-00920-4","url":null,"abstract":"<div><p>Individualized neoantigen-directed therapy represents a groundbreaking approach in melanoma treatment that leverages the patient’s own immune system to target cancer cells. This innovative strategy involves the identification of unique immunogenic neoantigens (mutated proteins specific to an individual’s tumor) and the development of therapeutic vaccines that either consist of peptide sequences or RNA encoding these neoantigens. The goal of these therapies is to induce neoantigen-specific immune responses, enabling the immune system to recognize and destroy cancer cells presenting the targeted neoantigens. This individualized approach is particularly advantageous given the genetic heterogeneity of melanoma, which exhibits distinct mutations among different patients. In contrast to traditional therapies, neoantigen-directed therapy offers a tailored treatment that potentially reduces off-target side effects and enhances therapeutic efficacy. Recent advances in neoantigen prediction and vaccine development have facilitated clinical trials exploring the combination of neoantigen vaccines with immune checkpoint inhibitors. These trials have shown promising clinical outcomes, underscoring the potential of this personalized approach. This review provides an overview of the rationale behind neoantigen-directed therapies and summarizes the current state of knowledge regarding personalized neoantigen vaccines in melanoma treatment.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 2","pages":"225 - 235"},"PeriodicalIF":8.6,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Family History on Clinical Presentation and Biologic Treatment Response in Patients with Psoriasis: A Multicenter Prospective Cohort Study
IF 8.6 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-22 DOI: 10.1007/s40257-025-00918-y
Yuxiong Jiang, Xiaoke Liu, Rui Ma, Dawei Huang, Yu Wang, Xiaoyuan Zhong, Lingling Yao, Shuang Xu, Ying Li, Xilin Zhang, Jiajing Lu, Yuling Shi

Background

Family history (FH) of psoriasis has been implicated as a risk factor for developing psoriasis. However, whether FH also carries information on clinical presentation and treatment response to biological agents in patients with psoriasis remains unclear.

Objective

This prospective, multicenter observational study aimed to analyze the clinical presentation and efficacy differences between patients with psoriasis with and without a FH.

Patients and Methods

The SPEECH registry is an observational, multicenter, and prospective registry that has been collecting data on psoriasis treatment since November 2022. This study included adult patients diagnosed with moderate-to-severe plaque psoriasis initiating treatment with biologics, including guselkumab, secukinumab, ixekizumab, ustekinumab, and adalimumab. FH of psoriasis was identified through patient self-report in which a positive FH was defined as a first-degree relative having psoriasis. The primary outcome measures include 75% improvement in Psoriasis Area and Severity Index (PASI75) and the Physician’s Global Assessment score of cleared/minimal (PGA 0/1) after 3 months of treatment. Logistic regression was employed to determine the adjusted odds ratios (aOR) and 95% confidence intervals (CI) for the achievement of response in selected outcomes for patients with a FH compared with those without a FH.

Results

The study included a total of 859 patients, of whom 22.9% had a FH of psoriasis. Patients with psoriasis who had a FH experienced an earlier onset of the disease and more severe anxiety symptoms than those without a FH. After 3 months of treatment, patients with psoriasis with a FH exhibited a higher likelihood of achieving PASI75 (aOR 1.60 [95% CI 1.02, 2.51]) and PGA 0/1 (aOR 1.54 [95% CI 1.03, 2.31]). Notably, these differences persisted after 6 months of treatment, confirming the sustained effectiveness of biologic treatments in patients with a positive FH. Further mediation analysis uncovered a significant indirect effect of FH on the treatment response to biologics through age of onset (p = 0.028), and the proportion mediated was 20.5%.

Conclusion

FH of psoriasis may affect the clinical course of patients and enhance their treatment response to biologics, highlighting the importance of FH assessment in optimizing treatment outcome and guiding clinical decision of biologic selection. Future studies on biologic treatment responses in psoriasis should consider family history as a significant confounding factor.

Chinese Clinical Trial Registry

ChiCTR2000036186.

{"title":"The Impact of Family History on Clinical Presentation and Biologic Treatment Response in Patients with Psoriasis: A Multicenter Prospective Cohort Study","authors":"Yuxiong Jiang,&nbsp;Xiaoke Liu,&nbsp;Rui Ma,&nbsp;Dawei Huang,&nbsp;Yu Wang,&nbsp;Xiaoyuan Zhong,&nbsp;Lingling Yao,&nbsp;Shuang Xu,&nbsp;Ying Li,&nbsp;Xilin Zhang,&nbsp;Jiajing Lu,&nbsp;Yuling Shi","doi":"10.1007/s40257-025-00918-y","DOIUrl":"10.1007/s40257-025-00918-y","url":null,"abstract":"<div><h3>Background</h3><p>Family history (FH) of psoriasis has been implicated as a risk factor for developing psoriasis. However, whether FH also carries information on clinical presentation and treatment response to biological agents in patients with psoriasis remains unclear.</p><h3>Objective</h3><p>This prospective, multicenter observational study aimed to analyze the clinical presentation and efficacy differences between patients with psoriasis with and without a FH.</p><h3>Patients and Methods</h3><p>The SPEECH registry is an observational, multicenter, and prospective registry that has been collecting data on psoriasis treatment since November 2022. This study included adult patients diagnosed with moderate-to-severe plaque psoriasis initiating treatment with biologics, including guselkumab, secukinumab, ixekizumab, ustekinumab, and adalimumab. FH of psoriasis was identified through patient self-report in which a positive FH was defined as a first-degree relative having psoriasis. The primary outcome measures include 75% improvement in Psoriasis Area and Severity Index (PASI75) and the Physician’s Global Assessment score of cleared/minimal (PGA 0/1) after 3 months of treatment. Logistic regression was employed to determine the adjusted odds ratios (aOR) and 95% confidence intervals (CI) for the achievement of response in selected outcomes for patients with a FH compared with those without a FH.</p><h3>Results</h3><p>The study included a total of 859 patients, of whom 22.9% had a FH of psoriasis. Patients with psoriasis who had a FH experienced an earlier onset of the disease and more severe anxiety symptoms than those without a FH. After 3 months of treatment, patients with psoriasis with a FH exhibited a higher likelihood of achieving PASI75 (aOR 1.60 [95% CI 1.02, 2.51]) and PGA 0/1 (aOR 1.54 [95% CI 1.03, 2.31]). Notably, these differences persisted after 6 months of treatment, confirming the sustained effectiveness of biologic treatments in patients with a positive FH. Further mediation analysis uncovered a significant indirect effect of FH on the treatment response to biologics through age of onset (<i>p</i> = 0.028), and the proportion mediated was 20.5%.</p><h3>Conclusion</h3><p>FH of psoriasis may affect the clinical course of patients and enhance their treatment response to biologics, highlighting the importance of FH assessment in optimizing treatment outcome and guiding clinical decision of biologic selection. Future studies on biologic treatment responses in psoriasis should consider family history as a significant confounding factor.</p><h3>Chinese Clinical Trial Registry</h3><p>ChiCTR2000036186.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 2","pages":"291 - 300"},"PeriodicalIF":8.6,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143021765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of Clinicopathological Features and Autoantibody Profiles in Patients with Cutaneous Lupus Erythematous: A Single-Center Retrospective Study 皮肤红斑狼疮患者的临床病理特征和自身抗体谱特征:一项单中心回顾性研究。
IF 8.6 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-19 DOI: 10.1007/s40257-024-00916-6
Svati Pazhyanur, Olivia Lamberg, Megan Hauptman, Jessica Cristiu, Noreen Khan, Allison C. Billi, Mio Nakamura
<div><h3>Background</h3><p>Cutaneous lupus erythematosus (CLE) is an autoimmune condition characterized by a wide range of clinical manifestations and limited treatment options. There is little research on the impact of commonly used diagnostic tests including antinuclear antibodies (ANA) and extractable nuclear antigens (ENA) on disease course or responsiveness to treatment.</p><h3>Objective</h3><p>This single-center retrospective cohort study aims to address this gap by characterizing clinicopathological characteristics, patient demographics, and treatment response among patients with CLE.</p><h3>Methods</h3><p>The study included patients with a diagnosis of CLE based on the International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10) codes evaluated in the outpatient clinics of the Department of Dermatology at Michigan Medicine between 1 January 2012 and 31 December 2022. Chart review was conducted to collect patient and clinical data including CLE subtype, patient demographics, disease course, presence of SLE, ANA and ENA results, and CLE treatments and response.</p><h3>Results</h3><p>390 patients with CLE were included, 86% (<i>n</i> = 334) of whom had biopsy-proven CLE. Most patients were female (77%), non-Hispanic (97%), and Caucasian (58%). Of all patients, 35% (<i>n</i> = 138) were ANA negative. The most common CLE treatments were antimalarials (86%, <i>n</i> = 336), topical steroids (85%, <i>n</i> = 331), systemic steroids (42%, <i>n</i> = 164), and mycophenolate mofetil (30%, <i>n</i> = 119). Treatment response was determined by clinician documentation and ranged from stabilization of disease to complete remission. Treatments with the highest CLE response rates included systemic steroids (84%, <i>n</i> = 138), antimalarials (63%, <i>n</i> = 212), belimumab (54%, <i>n</i> = 29), and topical steroids (50%, <i>n</i> = 165). Factors associated with lower response rates to antimalarials using chi-squared tests included anti-double stranded (ds) DNA (<i>n</i> = 54, 57% response among anti-dsDNA+ versus <i>n</i> = 165, 74% response among anti-dsDNA−), anti-Smith (<i>n</i> = 33, 54% versus <i>n</i> = 82, 72%), anti-RNP (<i>n</i> = 48, 56% versus <i>n</i> = 67, 73%), anti-SmRNP (<i>n</i> = 44, 54% versus <i>n</i> = 171, 74%), anti-chromatin (<i>n</i> = 33, 50% versus <i>n</i> = 179, 74%), SLE (<i>n</i> = 81, 57% versus <i>n</i> = 143, 79%), and ACLE subtype (<i>n</i> = 28, 58% versus <i>n</i> = 195, 71%). When controlling for demographics, CLE subtype, and presence of SLE using a logistic regression, factors associated with lower antimalarial response rates included anti-dsDNA (OR 0.5), anti-Smith (OR 0.5), and anti-chromatin (OR 0.6)</p><h3>Conclusion</h3><p>Our results suggest that numerous patient characteristics, namely the presence of ACLE, SLE, and its most commonly implicated autoantibodies (i.e., anti-dsDNA and anti-Smith), are associated with lower response rates to first-line therapies, including topica
背景:皮肤红斑狼疮(CLE)是一种自身免疫性疾病,具有广泛的临床表现和有限的治疗选择。关于常用的诊断试验,包括抗核抗体(ANA)和可提取核抗原(ENA)对病程或对治疗的反应性的影响的研究很少。目的:本单中心回顾性队列研究旨在通过描述CLE患者的临床病理特征、患者人口统计学特征和治疗反应来解决这一差距。方法:研究纳入了2012年1月1日至2022年12月31日期间在密歇根医学院皮肤科门诊诊所评估的基于国际疾病分类第九版(ICD-9)和第十版(ICD-10)代码诊断为CLE的患者。进行图表回顾以收集患者和临床数据,包括CLE亚型、患者人口统计学、病程、SLE的存在、ANA和ENA结果以及CLE治疗和反应。结果:纳入390例CLE患者,86% (n = 334)活检证实CLE。大多数患者为女性(77%)、非西班牙裔(97%)和白种人(58%)。在所有患者中,35% (n = 138)为ANA阴性。最常见的CLE治疗方法是抗疟药(86%,n = 336)、局部类固醇(85%,n = 331)、全身类固醇(42%,n = 164)和霉酚酸酯(30%,n = 119)。治疗反应由临床医生文件确定,范围从疾病稳定到完全缓解。CLE反应率最高的治疗包括全身类固醇(84%,n = 138)、抗疟药物(63%,n = 212)、贝利单抗(54%,n = 29)和局部类固醇(50%,n = 165)。因素相关的反应率较低的抗疟药物使用卡方测试包括anti-double链(ds) DNA (n = 54, 57%响应anti-dsDNA +与n = 165, 74% anti-dsDNA)之间的反应,anti-Smith (n = 33岁54% n = 82, 72%), anti-RNP (n = 48岁,56% n = 67, 73%), anti-SmRNP (n = 44岁54% n = 171, 74%), anti-chromatin (n = 33岁50% n = 179, 74%),系统性红斑狼疮(n = 81, 57% n = 143, 79%),和中国国际皮革展亚型(n = 28日58% n = 195, 71%)。当使用逻辑回归控制人口统计学、CLE亚型和SLE的存在时,与抗疟疾缓解率较低相关的因素包括抗dsdna (OR 0.5)、抗smith (OR 0.5)和抗染色质(OR 0.6)。我们的研究结果表明,许多患者的特征,即红斑狼疮、SLE及其最常见的自身抗体(即抗dsdna和抗smith)的存在,与一线治疗(包括局部类固醇和抗疟药)的低反应率相关。
{"title":"Characterization of Clinicopathological Features and Autoantibody Profiles in Patients with Cutaneous Lupus Erythematous: A Single-Center Retrospective Study","authors":"Svati Pazhyanur,&nbsp;Olivia Lamberg,&nbsp;Megan Hauptman,&nbsp;Jessica Cristiu,&nbsp;Noreen Khan,&nbsp;Allison C. Billi,&nbsp;Mio Nakamura","doi":"10.1007/s40257-024-00916-6","DOIUrl":"10.1007/s40257-024-00916-6","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Cutaneous lupus erythematosus (CLE) is an autoimmune condition characterized by a wide range of clinical manifestations and limited treatment options. There is little research on the impact of commonly used diagnostic tests including antinuclear antibodies (ANA) and extractable nuclear antigens (ENA) on disease course or responsiveness to treatment.&lt;/p&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;This single-center retrospective cohort study aims to address this gap by characterizing clinicopathological characteristics, patient demographics, and treatment response among patients with CLE.&lt;/p&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;The study included patients with a diagnosis of CLE based on the International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10) codes evaluated in the outpatient clinics of the Department of Dermatology at Michigan Medicine between 1 January 2012 and 31 December 2022. Chart review was conducted to collect patient and clinical data including CLE subtype, patient demographics, disease course, presence of SLE, ANA and ENA results, and CLE treatments and response.&lt;/p&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;390 patients with CLE were included, 86% (&lt;i&gt;n&lt;/i&gt; = 334) of whom had biopsy-proven CLE. Most patients were female (77%), non-Hispanic (97%), and Caucasian (58%). Of all patients, 35% (&lt;i&gt;n&lt;/i&gt; = 138) were ANA negative. The most common CLE treatments were antimalarials (86%, &lt;i&gt;n&lt;/i&gt; = 336), topical steroids (85%, &lt;i&gt;n&lt;/i&gt; = 331), systemic steroids (42%, &lt;i&gt;n&lt;/i&gt; = 164), and mycophenolate mofetil (30%, &lt;i&gt;n&lt;/i&gt; = 119). Treatment response was determined by clinician documentation and ranged from stabilization of disease to complete remission. Treatments with the highest CLE response rates included systemic steroids (84%, &lt;i&gt;n&lt;/i&gt; = 138), antimalarials (63%, &lt;i&gt;n&lt;/i&gt; = 212), belimumab (54%, &lt;i&gt;n&lt;/i&gt; = 29), and topical steroids (50%, &lt;i&gt;n&lt;/i&gt; = 165). Factors associated with lower response rates to antimalarials using chi-squared tests included anti-double stranded (ds) DNA (&lt;i&gt;n&lt;/i&gt; = 54, 57% response among anti-dsDNA+ versus &lt;i&gt;n&lt;/i&gt; = 165, 74% response among anti-dsDNA−), anti-Smith (&lt;i&gt;n&lt;/i&gt; = 33, 54% versus &lt;i&gt;n&lt;/i&gt; = 82, 72%), anti-RNP (&lt;i&gt;n&lt;/i&gt; = 48, 56% versus &lt;i&gt;n&lt;/i&gt; = 67, 73%), anti-SmRNP (&lt;i&gt;n&lt;/i&gt; = 44, 54% versus &lt;i&gt;n&lt;/i&gt; = 171, 74%), anti-chromatin (&lt;i&gt;n&lt;/i&gt; = 33, 50% versus &lt;i&gt;n&lt;/i&gt; = 179, 74%), SLE (&lt;i&gt;n&lt;/i&gt; = 81, 57% versus &lt;i&gt;n&lt;/i&gt; = 143, 79%), and ACLE subtype (&lt;i&gt;n&lt;/i&gt; = 28, 58% versus &lt;i&gt;n&lt;/i&gt; = 195, 71%). When controlling for demographics, CLE subtype, and presence of SLE using a logistic regression, factors associated with lower antimalarial response rates included anti-dsDNA (OR 0.5), anti-Smith (OR 0.5), and anti-chromatin (OR 0.6)&lt;/p&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;Our results suggest that numerous patient characteristics, namely the presence of ACLE, SLE, and its most commonly implicated autoantibodies (i.e., anti-dsDNA and anti-Smith), are associated with lower response rates to first-line therapies, including topica","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 2","pages":"265 - 273"},"PeriodicalIF":8.6,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment 特应性皮炎的生物标志物:IL-13的作用和曲洛单抗治疗的影响的综述
IF 8.6 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-16 DOI: 10.1007/s40257-024-00913-9
Joe Gorelick, Andrea Nguyen, Shannon K R Schneider, Britta C. Martel, Daniel E. Madsen, April W. Armstrong

Atopic dermatitis (AD) is a chronic, inflammatory skin disease that can significantly affect quality of life. Presence, severity, and therapeutic response of AD are traditionally reported through clinical assessments including the Eczema Area and Severity Index or Investigator’s Global Assessment. These clinical rating scales are visual assessments used in clinical trials to denotate AD severity. Alternatively, biomarkers open the potential to further enhance diagnosis of AD, assess disease status and severity, and potentially enable tailored treatment options for patients. Biomarkers can be classified according to their clinical use, clinical presentation, and underlying/endogenous molecular mechanisms. Specifically, interleukin (IL)-13, which has been shown to be a key biomarker in AD pathogenesis, can be used for prediction of AD development and to monitor clinical severity/response to treatment. Treatment with tralokinumab, a human monoclonal antibody that binds directly to—and subsequently blocks signaling of—IL-13, has been shown to reduce inflammation, re-balance the skin microbiome, and improve the skin barrier in patients with AD. In this review, key AD-related biomarkers, the role of IL-13 in driving AD pathogenesis, and the impact of IL-13 inhibition by tralokinumab on other AD-related biomarkers are discussed.

特应性皮炎(AD)是一种慢性炎症性皮肤病,可显著影响生活质量。AD的存在、严重程度和治疗反应传统上是通过临床评估来报告的,包括湿疹面积和严重程度指数或研究者的整体评估。这些临床评定量表是临床试验中用于表示AD严重程度的视觉评估。另外,生物标志物开启了进一步增强AD诊断、评估疾病状态和严重程度的潜力,并有可能为患者提供量身定制的治疗方案。生物标志物可根据其临床用途、临床表现和潜在/内源性分子机制进行分类。具体来说,白细胞介素(IL)-13已被证明是AD发病机制中的关键生物标志物,可用于预测AD的发展和监测临床严重程度/对治疗的反应。tralokinumab是一种人类单克隆抗体,直接结合并随后阻断il -13信号传导,已被证明可以减少AD患者的炎症,重新平衡皮肤微生物群,并改善皮肤屏障。本文综述了AD相关的关键生物标志物,IL-13在AD发病机制中的作用,以及曲罗单抗抑制IL-13对AD相关生物标志物的影响。
{"title":"Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment","authors":"Joe Gorelick,&nbsp;Andrea Nguyen,&nbsp;Shannon K R Schneider,&nbsp;Britta C. Martel,&nbsp;Daniel E. Madsen,&nbsp;April W. Armstrong","doi":"10.1007/s40257-024-00913-9","DOIUrl":"10.1007/s40257-024-00913-9","url":null,"abstract":"<div><p>Atopic dermatitis (AD) is a chronic, inflammatory skin disease that can significantly affect quality of life. Presence, severity, and therapeutic response of AD are traditionally reported through clinical assessments including the Eczema Area and Severity Index or Investigator’s Global Assessment. These clinical rating scales are visual assessments used in clinical trials to denotate AD severity. Alternatively, biomarkers open the potential to further enhance diagnosis of AD, assess disease status and severity, and potentially enable tailored treatment options for patients. Biomarkers can be classified according to their clinical use, clinical presentation, and underlying/endogenous molecular mechanisms. Specifically, interleukin (IL)-13, which has been shown to be a key biomarker in AD pathogenesis, can be used for prediction of AD development and to monitor clinical severity/response to treatment. Treatment with tralokinumab, a human monoclonal antibody that binds directly to—and subsequently blocks signaling of—IL-13, has been shown to reduce inflammation, re-balance the skin microbiome, and improve the skin barrier in patients with AD. In this review, key AD-related biomarkers, the role of IL-13 in driving AD pathogenesis, and the impact of IL-13 inhibition by tralokinumab on other AD-related biomarkers are discussed.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 2","pages":"199 - 211"},"PeriodicalIF":8.6,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-024-00913-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea 超越先驱补丁:探索玫瑰糠疹的复杂景观。
IF 8.6 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-11 DOI: 10.1007/s40257-024-00915-7
Kayla D. Mashoudy, Sarah Kim, Leah Farhadi, Scott A. Elman

Pityriasis rosea (PR) is a prevalent dermatological condition characterized by a distinctive herald patch, followed by secondary eruptions, often forming a “Christmas tree” pattern on the trunk. Despite its recognizable clinical presentation, the etiology of PR remains uncertain, with hypotheses pointing to both infectious and noninfectious origins. Human herpesviruses (HHV) 6 and 7 have been implicated, with evidence suggesting viral reactivation as a potential trigger. Epidemiologically, PR affects children, adolescents, and young adults, with a higher incidence in females. The condition is observed globally, with varying incidence rates and seasonal variations, suggesting an infectious component. While PR is generally benign and self-limiting, it can cause significant discomfort owing to pruritus, and atypical presentations and recurrences complicate diagnosis and management. This review evaluates the current understanding of PR’s pathogenesis, highlighting both infectious and noninfectious hypotheses, including viral reactivation and immune response mechanisms. It also examines treatment options, such as antivirals and phototherapy, which have shown varying degrees of effectiveness. Further research is needed to clarify etiological factors and to explore the efficacy and safety of various treatment modalities. Understanding these aspects is crucial for improving patient outcomes and developing targeted therapies, especially for atypical or recurrent cases.

玫瑰糠疹(PR)是一种常见的皮肤病,其特征是出现独特的先驱斑,随后出现继发疹,通常在树干上形成“圣诞树”图案。尽管其可识别的临床表现,但PR的病因学仍然不确定,假设指向感染性和非感染性起源。人类疱疹病毒(HHV) 6和7也有牵连,有证据表明病毒再激活是潜在的触发因素。在流行病学上,PR影响儿童、青少年和青壮年,女性发病率较高。这种情况在全球都有发现,发病率和季节变化各不相同,表明存在传染性成分。虽然PR通常是良性和自限性的,但由于瘙痒,它可引起明显的不适,非典型表现和复发使诊断和治疗复杂化。本文综述了目前对PR发病机制的理解,重点介绍了感染性和非感染性两种假说,包括病毒再激活和免疫反应机制。它还研究了治疗方案,如抗病毒药物和光疗,这些治疗方案显示出不同程度的有效性。需要进一步的研究来澄清病因,并探索各种治疗方式的有效性和安全性。了解这些方面对于改善患者预后和开发靶向治疗至关重要,特别是对于非典型或复发病例。
{"title":"Beyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea","authors":"Kayla D. Mashoudy,&nbsp;Sarah Kim,&nbsp;Leah Farhadi,&nbsp;Scott A. Elman","doi":"10.1007/s40257-024-00915-7","DOIUrl":"10.1007/s40257-024-00915-7","url":null,"abstract":"<div><p>Pityriasis rosea (PR) is a prevalent dermatological condition characterized by a distinctive herald patch, followed by secondary eruptions, often forming a “Christmas tree” pattern on the trunk. Despite its recognizable clinical presentation, the etiology of PR remains uncertain, with hypotheses pointing to both infectious and noninfectious origins. Human herpesviruses (HHV) 6 and 7 have been implicated, with evidence suggesting viral reactivation as a potential trigger. Epidemiologically, PR affects children, adolescents, and young adults, with a higher incidence in females. The condition is observed globally, with varying incidence rates and seasonal variations, suggesting an infectious component. While PR is generally benign and self-limiting, it can cause significant discomfort owing to pruritus, and atypical presentations and recurrences complicate diagnosis and management. This review evaluates the current understanding of PR’s pathogenesis, highlighting both infectious and noninfectious hypotheses, including viral reactivation and immune response mechanisms. It also examines treatment options, such as antivirals and phototherapy, which have shown varying degrees of effectiveness. Further research is needed to clarify etiological factors and to explore the efficacy and safety of various treatment modalities. Understanding these aspects is crucial for improving patient outcomes and developing targeted therapies, especially for atypical or recurrent cases.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 2","pages":"237 - 250"},"PeriodicalIF":8.6,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-024-00915-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142963458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis 鲁索利替尼乳膏在2-11岁中度至重度特应性皮炎患儿中的最大使用试验
IF 8.6 1区 医学 Q1 DERMATOLOGY Pub Date : 2025-01-06 DOI: 10.1007/s40257-024-00909-5
Linda Stein Gold, Robert Bissonnette, Seth Forman, Andrea Zaenglein, YuTzu Kuo, Brett Angel, Xuejun Chen, Howard Kallender, Amy S. Paller

Background

Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity and was well tolerated in a phase 3 study in patients aged 2–11 years with mild to moderate atopic dermatitis (AD).

Objective

This study examined the safety, tolerability, pharmacokinetics, efficacy, and quality of life (QoL) with ruxolitinib cream under maximum-use conditions and with longer-term use.

Methods

Eligible patients were aged 2–11 years with moderate to severe AD [Investigator’s Global Assessment (IGA) score 3–4], and ≥ 35% affected body surface area (BSA). Patients applied 1.5% ruxolitinib cream twice daily to all baseline-identified lesions during the 4-week maximum-use period, then to active lesions only up to week 52 (patients with ≤ 20% affected BSA from week 8). Safety was assessed by frequency and severity of adverse events. Pharmacokinetic parameters were assessed as secondary endpoints, and efficacy and QoL were exploratory endpoints.

Results

Overall, 29 patients (median age 5 years) were enrolled. Treatment-emergent adverse events were reported in 9/29 patients (31.0%); there were no adverse events of special interest (i.e., no serious infections, malignancies, major adverse cardiovascular events, or thromboses) during the study period. Mean steady-state plasma concentration during the maximum-use period was below the known half-maximal inhibitory concentration of Janus kinase–mediated myelosuppression in adults. Reductions in affected BSA and IGA observed at week 4 were sustained with as-needed use through 52 weeks. Improvements in patient-reported outcomes and QoL measures were consistent with efficacy results.

Conclusion

These results support the safety of ruxolitinib cream in children (2–11 years) with AD, including those with extensive disease, and are consistent with previous efficacy findings.

ClinicalTrials.gov Identifier

NCT05034822, first registered 30 August 2021.

背景:在一项针对2-11岁轻度至中度特应性皮炎(AD)患者的3期研究中,Ruxolitinib乳膏具有抗炎和止痒活性,且耐受性良好:本研究考察了芦可利替尼乳膏在最大使用量条件下和长期使用时的安全性、耐受性、药代动力学、疗效和生活质量(QoL):符合条件的患者年龄为2-11岁,患有中度至重度AD[研究者总体评估(IGA)评分3-4],受累体表面积(BSA)≥35%。在为期4周的最大使用期内,患者每天两次在所有基线确定的皮损处涂抹1.5%的芦可利替尼乳膏,然后仅在活动皮损处涂抹至第52周(从第8周开始,受影响体表面积≤20%的患者)。安全性根据不良反应的频率和严重程度进行评估。药代动力学参数为次要终点,疗效和 QoL 为探索性终点:共有 29 名患者(中位年龄为 5 岁)入组。9/29例患者(31.0%)报告了治疗突发不良事件;研究期间未发生特别值得关注的不良事件(即未发生严重感染、恶性肿瘤、重大心血管不良事件或血栓)。最大使用期内的平均稳态血浆浓度低于已知的成人 Janus 激酶介导的骨髓抑制的半最大抑制浓度。按需使用该药52周后,第4周观察到的受影响BSA和IGA降低情况得以持续。患者报告的结果和QoL指标的改善与疗效结果一致:这些结果支持芦可利替尼乳膏在儿童(2-11岁)AD患者(包括大面积疾病患者)中的安全性,并且与之前的疗效结果一致:Gov identifier:NCT05034822,2021年8月30日首次注册。
{"title":"A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis","authors":"Linda Stein Gold,&nbsp;Robert Bissonnette,&nbsp;Seth Forman,&nbsp;Andrea Zaenglein,&nbsp;YuTzu Kuo,&nbsp;Brett Angel,&nbsp;Xuejun Chen,&nbsp;Howard Kallender,&nbsp;Amy S. Paller","doi":"10.1007/s40257-024-00909-5","DOIUrl":"10.1007/s40257-024-00909-5","url":null,"abstract":"<div><h3>Background</h3><p>Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity and was well tolerated in a phase 3 study in patients aged 2–11 years with mild to moderate atopic dermatitis (AD).</p><h3>Objective</h3><p>This study examined the safety, tolerability, pharmacokinetics, efficacy, and quality of life (QoL) with ruxolitinib cream under maximum-use conditions and with longer-term use.</p><h3>Methods</h3><p>Eligible patients were aged 2–11 years with moderate to severe AD [Investigator’s Global Assessment (IGA) score 3–4], and ≥ 35% affected body surface area (BSA). Patients applied 1.5% ruxolitinib cream twice daily to all baseline-identified lesions during the 4-week maximum-use period, then to active lesions only up to week 52 (patients with ≤ 20% affected BSA from week 8). Safety was assessed by frequency and severity of adverse events. Pharmacokinetic parameters were assessed as secondary endpoints, and efficacy and QoL were exploratory endpoints.</p><h3>Results</h3><p>Overall, 29 patients (median age 5 years) were enrolled. Treatment-emergent adverse events were reported in 9/29 patients (31.0%); there were no adverse events of special interest (i.e., no serious infections, malignancies, major adverse cardiovascular events, or thromboses) during the study period. Mean steady-state plasma concentration during the maximum-use period was below the known half-maximal inhibitory concentration of Janus kinase–mediated myelosuppression in adults. Reductions in affected BSA and IGA observed at week 4 were sustained with as-needed use through 52 weeks. Improvements in patient-reported outcomes and QoL measures were consistent with efficacy results.</p><h3>Conclusion</h3><p>These results support the safety of ruxolitinib cream in children (2–11 years) with AD, including those with extensive disease, and are consistent with previous efficacy findings.</p><h3>ClinicalTrials.gov Identifier</h3><p>NCT05034822, first registered 30 August 2021.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 2","pages":"275 - 289"},"PeriodicalIF":8.6,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-024-00909-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acknowledgement to Referees 给推荐人的确认函。
IF 8.6 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-23 DOI: 10.1007/s40257-024-00914-8
{"title":"Acknowledgement to Referees","authors":"","doi":"10.1007/s40257-024-00914-8","DOIUrl":"10.1007/s40257-024-00914-8","url":null,"abstract":"","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 1","pages":"1 - 5"},"PeriodicalIF":8.6,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142875526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Biomarkers in Evolving Melanoma Immunotherapy 进化黑色素瘤免疫治疗的预后生物标志物。
IF 8.6 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-21 DOI: 10.1007/s40257-024-00910-y
Robin Reschke, Alexander H. Enk, Jessica C. Hassel

Melanoma, a highly aggressive form of skin cancer, has seen significant advancements in treatment through the introduction of immunotherapy. However, the variability in patient responses underscores the need for reliable biomarkers to guide treatment decisions. This article reviews key biomarkers in melanoma immunotherapy, such as PD-L1 expression, tumor mutational burden (TMB), and gene expression profiles (GEPs). It also explores emerging biomarkers, including LAG-3 expression, immune cell phenotyping in tissue and blood, gut microbiota, and circulating tumor DNA (ctDNA). Notably, ctDNA may offer valuable insights into the efficacy of T cell-engaging bispecific molecules, such as tebentafusp. The review provides a comprehensive overview of the evolving landscape of melanoma biomarkers, their role in personalizing treatment, and future research directions, including neoadjuvant immune checkpoint inhibition.

黑色素瘤是一种高度侵袭性的皮肤癌,通过引入免疫疗法,在治疗方面取得了重大进展。然而,患者反应的可变性强调了需要可靠的生物标志物来指导治疗决策。本文综述了黑色素瘤免疫治疗中的关键生物标志物,如PD-L1表达、肿瘤突变负荷(TMB)和基因表达谱(GEPs)。它还探讨了新兴的生物标志物,包括LAG-3表达、组织和血液中的免疫细胞表型、肠道微生物群和循环肿瘤DNA (ctDNA)。值得注意的是,ctDNA可能为T细胞参与双特异性分子(如tebentafusp)的功效提供有价值的见解。这篇综述全面概述了黑色素瘤生物标志物的发展前景,它们在个性化治疗中的作用,以及未来的研究方向,包括新辅助免疫检查点抑制。
{"title":"Prognostic Biomarkers in Evolving Melanoma Immunotherapy","authors":"Robin Reschke,&nbsp;Alexander H. Enk,&nbsp;Jessica C. Hassel","doi":"10.1007/s40257-024-00910-y","DOIUrl":"10.1007/s40257-024-00910-y","url":null,"abstract":"<div><p>Melanoma, a highly aggressive form of skin cancer, has seen significant advancements in treatment through the introduction of immunotherapy. However, the variability in patient responses underscores the need for reliable biomarkers to guide treatment decisions. This article reviews key biomarkers in melanoma immunotherapy, such as PD-L1 expression, tumor mutational burden (TMB), and gene expression profiles (GEPs). It also explores emerging biomarkers, including LAG-3 expression, immune cell phenotyping in tissue and blood, gut microbiota, and circulating tumor DNA (ctDNA). Notably, ctDNA may offer valuable insights into the efficacy of T cell-engaging bispecific molecules, such as tebentafusp. The review provides a comprehensive overview of the evolving landscape of melanoma biomarkers, their role in personalizing treatment, and future research directions, including neoadjuvant immune checkpoint inhibition.</p></div>","PeriodicalId":7706,"journal":{"name":"American Journal of Clinical Dermatology","volume":"26 2","pages":"213 - 223"},"PeriodicalIF":8.6,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40257-024-00910-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American Journal of Clinical Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1